LLY vs MYGN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
MYGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a fundamental collapse in financial health. While the balance sheet remains liquid with a strong current ratio (2.67) and low debt-to-equity (0.33), these are lagging indicators compared to the alarming -20.80% YoY revenue decline and -41.29% profit margin. The stock is in a long-term secular decline, losing over 82% of its value over five years, and current valuation is supported only by asset value (P/B 1.25) rather than earnings power.
Compare Another Pair
Related Comparisons
LLY vs MYGN: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Myriad Genetics, Inc. (MYGN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.